Form Type: 4

SEC EDGAR Link
Accession Number:0001127602-19-030385
Date:2019-10-08
Issuer: HAEMONETICS CORP (HAE)
Original Submission Date:

Reporting Person:

BASIL MICHELLE L
400 WOOD ROAD
BRAINTREE, MA 02184

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2019-10-08 S 8,883 d $122.34 23,771 direct
COMMON STOCK 2019-10-09 S 1,100 d $122.50 22,671 direct
COMMON STOCK 2019-10-09 S 3,724 d $123.50 18,947 direct
COMMON STOCK 2019-10-09 S 5,809 d $124.54 13,138 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
Footnotes
IDfootnote
f1 represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain performance share units previously reported in table i on october 8, 2019. this sale is mandated by the issuer's election under its 2005 long term incentive compensation plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
f2 this number includes unvested restricted stock units previously reported.
f3 transaction pursuant to an existing 10b5-1 trading plan.
f4 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $122.02 to $123.00, inclusive. the reporting person undertakes to provide to haemonetics corporation ("haemonetics"), any security holder of haemonetics, or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this form 4.
f5 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $123.09 to $124.02, inclusive.
f6 the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $124.09 to $124.96, inclusive.
WhaleWisdom Logo

Elevate your investments